Search results for "Asthma"

Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 t…

2017

Background: Reslizumab (RES), a humanized anti-interleukin-5 monoclonal antibody, has been demonstrated to significantly reduce the risk of clinical asthma exacerbation (CAE), and improve lung function, asthma symptoms and quality of life (QOL) in patients (pts) with inadequately controlled eosinophilic asthma (ICEA) and ≥1 CAE in the prior 12 mos despite standard of care therapy (Castro et al., Lancet Respir Med 2015; 3:355-366). Aims/Objectives: To assess the efficacy of RES in a subgroup of pts with ICEA who experienced only 1 CAE in the 12 mos prior to trial enrolment. Methods: This was a post-hoc analysis of the two duplicate 52-wk, placebo (PBO)-controlled phase 3 trials of RES (3 mg/…

1712 Serum Electrolytes Variations in Treated Patients with Moderate Asthma Exacerbation

2012

Background Salbutamol induces stimulation of beta 2 -receptors resulting in hypokalemia. Corticosteroids also induce plasma electrolytes variations. Aims To identify blood electrolytes changes following low dose inhaled short-acting beta 2 -agonists; To evaluate if concomitant inhaled corticosteroids treatment can amplify serum electrolytes changes. Methods We analyzed all children admitted for moderate asthma exacerbation during 6 months period. Inclusion criteria: children between 5–18 years of age; PEF >50–75% of predicted value; serum electrolytes normal ranges. Exclusion criteria: previously treated patients with Salbutamol; Salbutamol hypersensitivity; asthma exacerbation severity lev…

Industrial odour pollution and human health: a systematic review and meta-analysis.

2021

Abstract Objective To conduct a systematic review to evaluate the association between residential or occupational short- and long–term exposure to odour pollution from industrial sources and the health status of the exposed population. Methods The searches were conducted in Medline, EMBASE and Scopus in April 2021. Exposure to an environmental odour from industrial sources in population resident near the source or in workers was considered. We considered outcomes for which there was a biological plausibility, such as wheezing and asthma, cough, headache, nausea and vomiting (primary outcomes). We also included stress-related symptoms and novel outcomes (e.g. mood states). Risk of bias was e…

Predictors Of Asthma Control And A Risk Score For Exacerbations

2012

Basic self-reports as an indicator of physical activity

2016

Introduction: Basic self-reports of physical activity (PA) has been applied by clinicians to identify whether adolescents with asthma are physically active. Aim: To investigate whether basic self-reports of PA in adolescents with and without asthma can be used as an indicator of PA with objective measures as criterion. Methods: One-hundred-and sixty (99 boys) adolescents (mean age 13.5 yrs) with (n=88) and without (n=72) asthma completed recordings of PA for three consecutive week-days and one weekend-day using the SenseWear TM Pro 2 Armband (BodyMedia Inc., Pittsburgh, PA). Cut off point defining moderate to vigorous intensity PA (MVPA) was 3 metabolic equivalents. Self-reported PA was ass…

The Dietary Inflammatory Index and asthma burden in children: A latent class analysis

2021

Introduction: Unbalanced dietary intake has been increasingly recognized as an important modifiable risk factor for asthma. In this study, we assessed whether a pro-inflammatory diet is associated with higher asthma burden in three steps: (1) identification of asthma latent classes (LC) based on symptoms, indoor exposures, and pulmonary function; (2) identification of risk factors associated with LC membership; and (3) estimation of the probabilities of LC membership with variation in DII. Methods: A cross-sectional study on 415 children aged 5–14 years (266 with persistent asthma and 149 controls). LC analysis was performed in asthmatic children. The DII was calculated based on a semiquant…

Clinical evaluation and treatment of acute asthma exacerbations in children

2009

This update on treatment of asthma exacerbations in children is the result of an Italian Pediatric Society Task-force, made up of a panel of experts working in 2007–2008. The aim is to give clear indications on the use of the drugs most employed in children, grading the quality of evidence and the strength of recommendations. Suggestions on their limits due to unlicensed and off-label use are reported. The level of evidence and the strength of recommendations for different therapeutic approaches demonstrate that frequently the use of drugs in children is extrapolated from the experience in adults and that more studies are required to endorse the correct use of different drugs in asthmatic …

Safety and tolerability of omalizumab

2009

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic in…

The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma

2017

Introduction and Aim: As recognition of asthma heterogeneity increases and targeted treatment options are introduced, the future role of biomarkers (BM) in patient (pt) selection, monitoring and risk prediction will be important. We report baseline demographic and clinical characteristics from ARIETTA, an ongoing, prospective, longitudinal study assessing the relationship between BM and disease-related health outcomes in the real world. Methods: Pts with severe asthma (GINA steps 4-5) receiving daily inhaled corticosteroids (CS; fluticasone propionate ≥500 μg or equivalent) and ≥1 second controller medication were enrolled. Study enrollment is now complete. BM, clinical characteristics and …

Documento de consenso sobre asma y tabaquismo del Foro Autonómico de Asma de la SEPAR

2021

La prevalencia de tabaquismo activo en adultos con asma es similar a la de la población general. El tabaquismo se asocia con un peor control clínico de la enfermedad, una disminución acelerada de la función pulmonar y una respuesta irregular a la terapia con glucocorticoides. El consumo de tabaco impacta negativamente en la calidad de vida de los pacientes asmáticos y provoca un incremento en el número de visitas y de hospitalizaciones por exacerbaciones. Además, el tabaquismo aumenta el riesgo de cáncer de pulmón, comorbilidades cardiovasculares y muerte en pacientes asmáticos. A pesar de todo ello, las guías actuales del manejo del asma no incluyen recomendaciones específicas para el mane…